313 related articles for article (PubMed ID: 25592118)
1. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.
Park SJ; Oh J; Kim YK; Park JH; Park JY; Hong HK; Park KH; Lee JE; Kim HM; Chung JY; Woo SJ
Eye (Lond); 2015 Apr; 29(4):561-8. PubMed ID: 25592118
[TBL] [Abstract][Full Text] [Related]
2. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
Park SJ; Choi Y; Na YM; Hong HK; Park JY; Park KH; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2016 May; 57(6):2612-7. PubMed ID: 27258433
[TBL] [Abstract][Full Text] [Related]
3. Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs.
Joo K; Park SJ; Choi Y; Lee JE; Na YM; Hong HK; Park KH; Kim HM; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4261-4267. PubMed ID: 28850637
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
[TBL] [Abstract][Full Text] [Related]
5. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
9. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study.
Lashay A; Delrish E; Ashrafi E; Movassat M; Asadi-Amoli F; Dinarvand R; Abrishami M
Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):785-790. PubMed ID: 31877224
[TBL] [Abstract][Full Text] [Related]
10. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
14. Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats.
Jakubiak P; Alvarez-Sánchez R; Fueth M; Broders O; Kettenberger H; Stubenrauch K; Caruso A
Mol Pharm; 2021 Jun; 18(6):2208-2217. PubMed ID: 34014104
[TBL] [Abstract][Full Text] [Related]
15. In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates.
Jiang J; Wang L; Kou X; Liu Z; Huang M; Li H; Wu C
Exp Eye Res; 2020 Jan; 190():107823. PubMed ID: 31600485
[TBL] [Abstract][Full Text] [Related]
16. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
Kakinoki M; Sawada O; Sawada T; Saishin Y; Kawamura H; Ohji M
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5877-80. PubMed ID: 22836776
[TBL] [Abstract][Full Text] [Related]
17. Predicted biological activity of intravitreal VEGF Trap.
Stewart MW; Rosenfeld PJ
Br J Ophthalmol; 2008 May; 92(5):667-8. PubMed ID: 18356264
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.
Ahn J; Kim H; Woo SJ; Park JH; Park S; Hwang DJ; Park KH
J Ocul Pharmacol Ther; 2013 Sep; 29(7):612-8. PubMed ID: 23735192
[TBL] [Abstract][Full Text] [Related]
19. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.
Moisseiev E; Waisbourd M; Ben-Artsi E; Levinger E; Barak A; Daniels T; Csaky K; Loewenstein A; Barequet IS
Graefes Arch Clin Exp Ophthalmol; 2014 Feb; 252(2):331-7. PubMed ID: 24170282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]